New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain
TN affects the trigeminal or 5th cranial nerve which carries sensation from the face to the brain, triggering pain in the lower face and jaw, in areas above the eyes or around the nose. One of the most common causes of TN is compression of the nerve by a blood vessel, but there are multiple other causes including a tumor constricting the nerve, surgical injury or stroke. The unpredictable, intense pain patients experience can make living with TN challenging and can lead to weight loss, depression and isolation2.
"Trigeminal neuralgia has the potential to significantly disrupt patients' daily lives if left untreated or inadequately treated. That's why the health insurance reimbursement approval for the CyberKnife System is so important," said
People diagnosed with TN require long-term medical care that usually starts with medication to lessen or block the pain signals sent to the brain. Over time, the pain control provided by these drugs diminishes for some patients and others experience unpleasant side effects. For these patients, injections, surgery, or radiosurgery may be necessary.
"Although trigeminal neuralgia is a rare disease with an incidence of about 5 out of 100,000 people, or approximately 5,000 people in
The CyberKnife System was initially designed by a neurosurgeon for neurosurgeons to treat diseases in the head, the skull base and the spine such as benign and malignant primary tumors, brain metastases, meningiomas, trigeminal neuralgia, acoustic neuromas and arteriovenous malformations (AVMs). The platform's unique robotic technology, non-coplanar beam delivery and Synchrony® motion adaptation technology enable the delivery of radiation with sub-millimeter accuracy, meaning minimal radiation is delivered to the surrounding healthy tissue. Since its introduction the CyberKnife® System has evolved into a full-body radiosurgery system that enables consistent delivery of extremely precise treatments to tumors throughout the body, including those in the kidney, liver, lung, pancreas, prostate, bone metastases and oligo metastases.
For Important Safety Information, please refer to https://www.accuray.com/safety-statement.
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, the CyberKnife platform's potential for the treatment of trigeminal neuralgia, clinical applications, clinical results, patient experiences and outcomes, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director,
+1 (408) 789-4426
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-reimbursement-approved-by-the-japanese-ministry-of-health-labor-and-welfare-for-the-accuray-cyberknife-system-to-treat-trigeminal-neuralgia-a-condition-often-causing-severe-facial-pain-301659442.html